| This week's sponsor is CMIC Group. | |  | Considering Japanese Market Entry?
As Japan's largest CRO with end-to-end solution, CMIC Group is your most experienced partner in Japan & the US. Our experts will help you determine the best strategy at any stage of drug development.
Click here to learn more! |
Today's Rundown Featured Story | | | Friday, March 1, 2019 A phase 3 trial of ImmunoGen’s antibody-drug conjugate mirvetuximab soravtansine has missed its primary endpoint. The ADC failed to extend progression-free survival more than chemotherapy, driving investors to wipe 50% off its stock price. |
|
|
| This week's sponsor is Sprout BioVentures. | |  | Final Week for Golden Sprout Competition
Don’t miss out on 6 months of chemistry support at no cost. Strengthen your chemical starting points and work with a world-class research organization trusted by global biopharma. Click here to download the application. |
Top Stories Friday, March 1, 2019 Gilead’s Kite Pharma has expanded its CAR-T agreement with MaxCyte. The revised deal gives Kite the chance to apply MaxCyte’s transfection technology to up to 10 targets. Friday, March 1, 2019 Ascletis has enticed a big pharma veteran to serve as its new head of R&D, with former MSD China global VP Zhengqing Li taking on the task. Monday, February 25, 2019 Biologics have experienced steady double-digit growth over the last 15 years and now comprise slightly more than a quarter of all New Molecular Entity (NME) FDA approvals. Thursday, February 28, 2019 A head-to-head study pitting Guardant Health’s lung cancer blood test against standard, tissue-based testing found that the liquid biopsy was able to deliver similar results much faster and with more accuracy—which Guardant says makes the case for its blood-based genomic test to be performed first for all newly diagnosed patients. Thursday, February 28, 2019 In this week's EuroBiotech Report, Ipsen has struck a $1.3 billion takeover of Clementia, Novartis is licensing a cardiovascular drug and Anaveon has raised $35 million. Friday, March 1, 2019 Daiichi names new global R&D chief and U.S. CEO to drive collaboration between R&D and commercial; China approves the country's first biosimilar, a Rituxan copy made by a Fosun Pharma subsidiary; Sinovac uses a rare "poison pill" defense to keep rebel investors' takeover attempt at bay. Friday, March 1, 2019 Daiichi Sankyo makes changes to its U.S. research unit; Immunomedics' CEO quits; and Parexel nabs another key FDA oncology staffer. Those moves plus more hirings, firings and retirings throughout the industry. Resources Sponsored by: Patheon, part of Thermo Fisher Scientific The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing. Sponsored by: Patheon, part of Thermo Fisher Scientific Download this whitepaper to learn more. Sponsored by: ON24 Which HCP Touchpoints and channels are yielding the best results in today’s digital world? Sponsored by: Blue Matter White paper outlining the key types of cell-based immunotherapies in oncology, as well as the development and commercial outlook for each. Sponsored by: AlphaSense It’s never been more challenging to stay on top of trends and innovation shaping the future of healthcare. Discover how AI can help competitive intelligence teams achieve more proactive strategies. Sponsored by: Cofactor Genomics Learn how Health Expression Models provide increased sensitivity, specificity, and accuracy for characterizing immune response in solid tumor specimens. Sponsored by: BioAnalytix, Inc. This whitepaper reviews fundamental aspects of HCPs that pertain to biologic drug development and presents current and emerging approaches to HCP analysis. Sponsored by: Outer Edge Technology With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market. Presented by: Veeva Share your thoughts on the life sciences industry's progress in improving study execution. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
